The consequences of PCSK9 inhibition in selected tissues

[1] Abifadel M., Varret M., Rabès J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., Derré A., Villéger L., Farnier M., Beucler I., Bruckert E. i wsp.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003; 34: 154–156 AbifadelM. VarretM. RabèsJ.P. AllardD. OuguerramK. DevillersM. CruaudC. BenjannetS. WickhamL. ErlichD. DerréA. VillégerL. FarnierM. BeuclerI. BruckertE. i wsp. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat. Genet. 2003 34 154 156 10.1038/ng116112730697 Search in Google Scholar

[2] Adorni M.P., Cipollari E., Favari E., Zanotti I., Zimetti F., Corsini A., Ricci C., Bernini F., Ferri N.: Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis, 2017; 256: 1–6 AdorniM.P. CipollariE. FavariE. ZanottiI. ZimettiF. CorsiniA. RicciC. BerniniF. FerriN. Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages Atherosclerosis 2017 256 1 6 10.1016/j.atherosclerosis.2016.11.01927940374 Search in Google Scholar

[3] An D., Wei X., Li H., Gu H., Huang T., Zhao G., Liu B., Wang W., Chen L., Ma W., Zhang H., Cao S., Yuan Z.: Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. Sci. Rep., 2015; 5: 17559 AnD. WeiX. LiH. GuH. HuangT. ZhaoG. LiuB. WangW. ChenL. MaW. ZhangH. CaoS. YuanZ. Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics Sci. Rep. 2015 5 17559 10.1038/srep17559468691326691006 Search in Google Scholar

[4] Arama C., Diarra I., Kouriba B., Sirois F., Fedoryak O., Thera M.A., Coulibaly D., Lyke K.E., Plowe C.V., Chrétien M., Doumbo O.K., Mbikay M.: Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. PLoS One, 2018; 13: e0192850 AramaC. DiarraI. KouribaB. SiroisF. FedoryakO. TheraM.A. CoulibalyD. LykeK.E. PloweC.V. ChrétienM. DoumboO.K. MbikayM. Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children PLoS One 2018 13 e0192850 10.1371/journal.pone.0192850581395529447211 Search in Google Scholar

[5] Bai X.Q., Peng J., Wang M.M., Xiao J., Xiang Q., Ren Z., Wen H.Y., Jiang Z.S., Tang Z.H., Liu L.S.: PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis? Clin. Chim. Acta, 2018; 483: 192–196 BaiX.Q. PengJ. WangM.M. XiaoJ. XiangQ. RenZ. WenH.Y. JiangZ.S. TangZ.H. LiuL.S. PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis? Clin. Chim. Acta 2018 483 192 196 10.1016/j.cca.2018.04.04029727700 Search in Google Scholar

[6] Banach M., Rizzo M., Nikolic D., Howard G., Howard V.J., Mikhailidis D.P.: Intensive LDL-cholesterol lowering therapy and neurocognitive function. Pharmacol. Ther., 2017; 170: 181–191 BanachM. RizzoM. NikolicD. HowardG. HowardV.J. MikhailidisD.P. Intensive LDL-cholesterol lowering therapy and neurocognitive function Pharmacol. Ther. 2017 170 181 191 10.1016/j.pharmthera.2016.11.00127865998 Search in Google Scholar

[7] Barale C., Bonomo K., Frascaroli C., Morotti A., Guerrasio A., Cavalot F., Russo I.: Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutr. Metab. Cardiovasc. Dis., 2020; 30: 282–291 BaraleC. BonomoK. FrascaroliC. MorottiA. GuerrasioA. CavalotF. RussoI. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up Nutr. Metab. Cardiovasc. Dis. 2020 30 282 291 10.1016/j.numecd.2019.09.01231653513 Search in Google Scholar

[8] Berger J.M., Vaillant N., Le May C., Calderon C., Brégeon J., Prieur X., Hadchouel J., Loirand G., Cariou B.: PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis, 2015; 239: 252–259 BergerJ.M. VaillantN. Le MayC. CalderonC. BrégeonJ. PrieurX. HadchouelJ. LoirandG. CariouB. PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension Atherosclerosis 2015 239 252 259 10.1016/j.atherosclerosis.2015.01.01225621930 Search in Google Scholar

[9] Besseling J., Kastelein J.J., Defesche J.C., Hutten B.A., Hovingh G.K.: Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA, 2015; 313: 1029–1036 BesselingJ. KasteleinJ.J. DefescheJ.C. HuttenB.A. HovinghG.K. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus JAMA 2015 313 1029 1036 10.1001/jama.2015.120625756439 Search in Google Scholar

[10] Blom D.J., Djedjos C.S., Monsalvo M.L., Bridges I., Wasserman S.M., Scott R., Roth E.: Effects of evolocumab on vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ. Res., 2015; 117: 731–741 BlomD.J. DjedjosC.S. MonsalvoM.L. BridgesI. WassermanS.M. ScottR. RothE. Effects of evolocumab on vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study Circ. Res. 2015 117 731 741 10.1161/CIRCRESAHA.115.30707126228031 Search in Google Scholar

[11] Blom D.J., Hala T., Bolognese M., Lillestol M.J., Toth P.D., Burgess L., Ceska R., Roth E., Koren M.J., Ballantyne C.M., Monsalvo M.L., Tsirtsonis K., Kim J.B., Scott R., Wasserman S.M.: A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med., 2014; 370: 1809–1819 BlomD.J. HalaT. BologneseM. LillestolM.J. TothP.D. BurgessL. CeskaR. RothE. KorenM.J. BallantyneC.M. MonsalvoM.L. TsirtsonisK. KimJ.B. ScottR. WassermanS.M. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N. Engl. J. Med. 2014 370 1809 1819 10.1056/NEJMoa1316222 Search in Google Scholar

[12] Boyd J.H., Fjell C.D., Russell J.A., Sirounis D., Cirstea M.S., Walley K.R.: Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis. J. Innate Immun., 2016; 8: 211–220 BoydJ.H. FjellC.D. RussellJ.A. SirounisD. CirsteaM.S. WalleyK.R. Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis J. Innate Immun. 2016 8 211 220 10.1159/000442976 Search in Google Scholar

[13] Bułdak Ł., Marek B., Kajdaniuk D., Urbanek A., Janyga S., Bołdys A., Basiak M., Maligłówka M., Okopień B.: Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol. Pol., 2019; 70: 511–519 BułdakŁ. MarekB. KajdaniukD. UrbanekA. JanygaS. BołdysA. BasiakM. MaligłówkaM. OkopieńB. Endocrine diseases as causes of secondary hyperlipidemia Endokrynol. Pol. 2019 70 511 519 10.5603/EP.a2019.0041 Search in Google Scholar

[14] Campbell J.H., Popadynec L., Nestel P.J., Campbell G.R.: Lipid accumulation in arterial smooth muscle cells. Influence of phenotype. Atherosclerosis, 1983; 47: 279–295 CampbellJ.H. PopadynecL. NestelP.J. CampbellG.R. Lipid accumulation in arterial smooth muscle cells. Influence of phenotype Atherosclerosis 1983 47 279 295 10.1016/0021-9150(83)90059-X Search in Google Scholar

[15] Cariou B., Benoit I., Le May C.: Preserved adrenal function in fully PCSK9-deficient subject. Int. J. Cardiol., 2014; 176: 499–500 CariouB. BenoitI. Le MayC. Preserved adrenal function in fully PCSK9-deficient subject Int. J. Cardiol. 2014 176 499 500 10.1016/j.ijcard.2014.07.05725062564 Search in Google Scholar

[16] Cederberg H., Stančáková A., Yaluri N., Modi S., Kuusisto J., Laakso M.: Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6-year follow-up study of the METSIM cohort. Diabetologia, 2015; 58: 1109–1117 CederbergH. StančákováA. YaluriN. ModiS. KuusistoJ. LaaksoM. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6-year follow-up study of the METSIM cohort Diabetologia 2015 58 1109 1117 10.1007/s00125-015-3528-525754552 Search in Google Scholar

[17] Chang T.J., Chiu Y.F., Sheu W.H., Shih K.C., Hwu C.M., Quertermous T., Jou Y.S., Kuo S.S., Chang Y.C., Chuang L.M.: Genetic polymorphisms of PCSK2 are associated with glucose homeostasis and progression to type 2 diabetes in a Chinese population. Sci. Rep., 2015; 5: 14380 ChangT.J. ChiuY.F. SheuW.H. ShihK.C. HwuC.M. QuertermousT. JouY.S. KuoS.S. ChangY.C. ChuangL.M. Genetic polymorphisms of PCSK2 are associated with glucose homeostasis and progression to type 2 diabetes in a Chinese population Sci. Rep. 2015 5 14380 10.1038/srep14380466038426607656 Search in Google Scholar

[18] Chen S., Cao P., Dong N., Peng J., Zhang C., Wang H., Zhou T., Yang J., Zhang Y., Martelli E.E., Naga Prasad S.V., Miller R.E., Malfait A.M., Zhou Y., Wu Q.: PCSK6-mediated corin activation is essential for normal blood pressure. Nat. Med., 2015; 21: 1048–1053 ChenS. CaoP. DongN. PengJ. ZhangC. WangH. ZhouT. YangJ. ZhangY. MartelliE.E. Naga PrasadS.V. MillerR.E. MalfaitA.M. ZhouY. WuQ. PCSK6-mediated corin activation is essential for normal blood pressure Nat. Med. 2015 21 1048 1053 10.1038/nm.3920471051726259032 Search in Google Scholar

[19] Cheng J.M., Oemrawsingh R.M., Garcia-Garcia H.M., Boersma E., van Geuns R.J., Serruys P.W., Kardys I., Akkerhuis K.M.: PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMOIVUS study. Atherosclerosis, 2016; 248: 117–122 ChengJ.M. OemrawsinghR.M. Garcia-GarciaH.M. BoersmaE. van GeunsR.J. SerruysP.W. KardysI. AkkerhuisK.M. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMOIVUS study Atherosclerosis 2016 248 117 122 10.1016/j.atherosclerosis.2016.03.01027015246 Search in Google Scholar

[20] Cohen J.C., Boerwinkle E., Mosley T.H. Jr, Hobbs H.H.: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med., 2006; 354: 1264–1272 CohenJ.C. BoerwinkleE. MosleyT.H.Jr HobbsH.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N. Engl. J. Med. 2006 354 1264 1272 10.1056/NEJMoa05401316554528 Search in Google Scholar

[21] D’Ardes D., Santilli F., Guagnano M.T., Bucci M., Cipollone F.: From endothelium to lipids, through microRNAs and PCSK9: A fascinating travel across atherosclerosis. High Blood Press. Cardiovasc. Prev., 2020; 27: 1–8 D’ArdesD. SantilliF. GuagnanoM.T. BucciM. CipolloneF. From endothelium to lipids, through microRNAs and PCSK9: A fascinating travel across atherosclerosis. High Blood Press Cardiovasc. Prev. 2020 27 1 8 Search in Google Scholar

[22] de Carvahlo L.S., Campos A.M., Sposito A.C.: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: A systematic review and meta-analysis with over 96,000 patient-years. Diabetes Care, 2018; 41: 364–367 de CarvahloL.S. CamposA.M. SpositoA.C. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: A systematic review and meta-analysis with over 96,000 patient-years Diabetes Care 2018 41 364 367 10.2337/dc17-146429180351 Search in Google Scholar

[23] Denis M., Marcinkiewicz J., Zaid A., Gauthier D., Poirier S., Lazure C., Seidah N.G., Prat A.: Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation, 2012; 125: 894–901 DenisM. MarcinkiewiczJ. ZaidA. GauthierD. PoirierS. LazureC. SeidahN.G. PratA. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice Circulation 2012 125 894 901 10.1161/CIRCULATIONAHA.111.05740622261195 Search in Google Scholar

[24] Diedrich G.: How does hepatitis C virus enter cells? FEBS J., 2006; 273: 3871–3885 DiedrichG. How does hepatitis C virus enter cells? FEBS J. 2006 273 3871 3885 10.1111/j.1742-4658.2006.05379.x16934030 Search in Google Scholar

[25] Ding Z., Liu S., Wang X., Deng X., Fan Y., Shahanawaz J., Shmookler Reis R.J., Varughese K.I., Sawamura T., Mehta J.L.: Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc. Res., 2015; 107: 556–567 DingZ. LiuS. WangX. DengX. FanY. ShahanawazJ. Shmookler ReisR.J. VarugheseK.I. SawamuraT. MehtaJ.L. Cross-talk between LOX-1 and PCSK9 in vascular tissues Cardiovasc. Res. 2015 107 556 567 10.1093/cvr/cvv17826092101 Search in Google Scholar

[26] Ding Z., Liu S., Wang X., Theus S., Deng X., Fan Y., Zhou S., Mehta J.L.: PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovasc. Res., 2018; 114: 1145–1153 DingZ. LiuS. WangX. TheusS. DengX. FanY. ZhouS. MehtaJ.L. PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages Cardiovasc. Res. 2018 114 1145 1153 10.1093/cvr/cvy07929617722 Search in Google Scholar

[27] Dyrbuś K., Gąsior M., Penson P., Ray K.K., Banach M.: Inclisiran – New hope in the management of lipid disorders? J. Clin. Lipidol., 2020; 14: 16–27 DyrbuśK. GąsiorM. PensonP. RayK.K. BanachM. Inclisiran – New hope in the management of lipid disorders? J. Clin. Lipidol. 2020 14 16 27 10.1016/j.jacl.2019.11.00131879073 Search in Google Scholar

[28] Feingold K.R., Moser A.H., Shigenaga J.K., Patzek S.M., Grunfeld C.: Inflammation stimulates the expression of PCSK9. Biochem. Biophys. Res. Commun., 2008; 374: 341–344 FeingoldK.R. MoserA.H. ShigenagaJ.K. PatzekS.M. GrunfeldC. Inflammation stimulates the expression of PCSK9 Biochem. Biophys. Res. Commun. 2008 374 341 344 10.1016/j.bbrc.2008.07.023257108118638454 Search in Google Scholar

[29] Ferri N., Tibolla G., Pirillo A., Cipollone F., Mezzetti A., Pacia S., Corsini A., Catapano A.L.: Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis, 2012; 220: 381–386 FerriN. TibollaG. PirilloA. CipolloneF. MezzettiA. PaciaS. CorsiniA. CatapanoA.L. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels Atherosclerosis 2012 220 381 386 10.1016/j.atherosclerosis.2011.11.02622176652 Search in Google Scholar

[30] Gencer B., Kronenberg F., Stroes E.S., Mach F.: Lipoprotein(a): The revenant. Eur. Heart J., 2017; 38: 1553–1560 GencerB. KronenbergF. StroesE.S. MachF. Lipoprotein(a): The revenant Eur. Heart J. 2017 38 1553 1560 10.1093/eurheartj/ehx03328329241 Search in Google Scholar

[31] Gencer B., Mach F., Guo J., Im K., Ruzza A., Wang H., Kurtz C.E., Pedersen T.R., Keech A.C., Ott B.R., Sabatine M.S., Giugliano R.P., FOURIER Investigators: Cognition after lowering LDL-cholesterol with evolocumab. J. Am. Coll. Cardiol., 2020; 75: 2283–2293 GencerB. MachF. GuoJ. ImK. RuzzaA. WangH. KurtzC.E. PedersenT.R. KeechA.C. OttB.R. SabatineM.S. GiuglianoR.P. FOURIER Investigators Cognition after lowering LDL-cholesterol with evolocumab J. Am. Coll. Cardiol. 2020 75 2283 2293 10.1016/j.jacc.2020.03.03932381158 Search in Google Scholar

[32] Geovanini G.R., Libby P.: Atherosclerosis and inflammation: Overview and updates. Clin. Sci., 2018; 132: 1243–1252 GeovaniniG.R. LibbyP. Atherosclerosis and inflammation: Overview and updates Clin. Sci. 2018 132 1243 1252 10.1042/CS20180306 Search in Google Scholar

[33] German C.A., Shapiro M.D.: Small interfering RNA therapeutic inclisiran: A new approach to targeting PCSK9. BioDrugs, 2020; 34: 1–9 GermanC.A. ShapiroM.D. Small interfering RNA therapeutic inclisiran: A new approach to targeting PCSK9 BioDrugs 2020 34 1 9 10.1007/s40259-019-00399-6 Search in Google Scholar

[34] Giugliano R.P., Desai N.R., Kohli P., Rogers W.J., Somaratne R., Huang F., Liu T., Mohanavelu S., Hoffman E.B., McDonald S.T., Abrahamsen T.E., Wasserman S.M., Scott R., Sabatine M.S., LAPLACE-TIMI 57 Investigators: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet, 2012; 380: 2007–2017 GiuglianoR.P. DesaiN.R. KohliP. RogersW.J. SomaratneR. HuangF. LiuT. MohanaveluS. HoffmanE.B. McDonaldS.T. AbrahamsenT.E. WassermanS.M. ScottR. SabatineM.S. LAPLACE-TIMI 57 Investigators Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 2012 380 2007 2017 10.1016/S0140-6736(12)61770-X Search in Google Scholar

[35] Giugliano R.P., Pedersen T.R., Saver J.L., Sever P.S., Keech A.C., Bohula E.A., Murphy S.A., Wasserman S.M., Honarpour N., Wang H., Pineda A.L., Sabatine M.S., FOURIER Investigators: Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke, 2020; 51: 1546–1554 GiuglianoR.P. PedersenT.R. SaverJ.L. SeverP.S. KeechA.C. BohulaE.A. MurphyS.A. WassermanS.M. HonarpourN. WangH. PinedaA.L. SabatineM.S. FOURIER Investigators Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis Stroke 2020 51 1546 1554 10.1161/STROKEAHA.119.02775932312223 Search in Google Scholar

[36] Guillemot J., Essalmani R., Hamelin J., Seidah N.G.: Is there a link between proprotein convertase PC7 activity and human lipid homeostasis? FEBS Open Bio, 2014; 4: 741–745 GuillemotJ. EssalmaniR. HamelinJ. SeidahN.G. Is there a link between proprotein convertase PC7 activity and human lipid homeostasis? FEBS Open Bio 2014 4 741 745 10.1016/j.fob.2014.08.004420809325349778 Search in Google Scholar

[37] Haas M.E., Levenson A.E., Sun X., Liao W.H., Rutkowski J.M., de Ferranti S.D., Schumacher V.A., Scherer P.E., Salant D.J., Biddinger S.B.: The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation, 2016; 134: 61–72 HaasM.E. LevensonA.E. SunX. LiaoW.H. RutkowskiJ.M. de FerrantiS.D. SchumacherV.A. SchererP.E. SalantD.J. BiddingerS.B. The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia Circulation 2016 134 61 72 10.1161/CIRCULATIONAHA.115.020912534585327358438 Search in Google Scholar

[38] Hoac B., Susan-Resiga D., Essalmani R., Marcinkiweicz E., Seidah N.G., McKee M.D.: Osteopontin as a novel substrate for the proprotein convertase 5/6 (PCSK5) in bone. Bone, 2018; 107: 45–55 HoacB. Susan-ResigaD. EssalmaniR. MarcinkiweiczE. SeidahN.G. McKeeM.D. Osteopontin as a novel substrate for the proprotein convertase 5/6 (PCSK5) in bone Bone 2018 107 45 55 10.1016/j.bone.2017.11.00229126984 Search in Google Scholar

[39] Hu J., Zhang Z., Shen W.J., Azhar S.: Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr. Metab., 2010; 7: 47 HuJ. ZhangZ. ShenW.J. AzharS. Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones Nutr. Metab. 2010 7 47 10.1186/1743-7075-7-47289069720515451 Search in Google Scholar

[40] Izaguirre G.: The proteolytic regulation of virus cell entry by furin and other proprotein convertases. Viruses, 2019; 11: 837 IzaguirreG. The proteolytic regulation of virus cell entry by furin and other proprotein convertases Viruses 2019 11 837 10.3390/v11090837678429331505793 Search in Google Scholar

[41] Karagiannis A.D., Liu M., Toth P.P., Zhao S., Agrawal D.K., Libby P., Chatzizisis Y.S.: Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation. Curr. Atheroscler. Rep., 2018; 20: 20 KaragiannisA.D. LiuM. TothP.P. ZhaoS. AgrawalD.K. LibbyP. ChatzizisisY.S. Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation Curr. Atheroscler. Rep. 2018 20 20 10.1007/s11883-018-0718-x29525934 Search in Google Scholar

[42] Khademi F., Momtazi-Borojeni A.A., Reiner Ž., Banach M., Al-Rasadi K.A., Sahebkar A.: PCSK9 and infection: A potentially useful or dangerous association? J. Cell. Pysiol., 2018; 233: 2920–2927 KhademiF. Momtazi-BorojeniA.A. ReinerŽ. BanachM. Al-RasadiK.A. SahebkarA. PCSK9 and infection: A potentially useful or dangerous association? J. Cell. Pysiol. 2018 233 2920 2927 10.1002/jcp.26040 Search in Google Scholar

[43] Kockx M., Kritharides L.: Pancreatic PCSK9 and its involvement in diabetes. J. Thorac. Dis., 2019; 11: S2018–S2022 KockxM. KritharidesL. Pancreatic PCSK9 and its involvement in diabetes J. Thorac. Dis. 2019 11 S2018 S2022 10.21037/jtd.2019.06.37 Search in Google Scholar

[44] Koren M.J., Scott R., Kim J.B., Knusel B., Liu T., Lei L., Bolognese M., Wasserman S.M.: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as mono-therapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study. Lancet, 2012; 380: 1995–2006 KorenM.J. ScottR. KimJ.B. KnuselB. LiuT. LeiL. BologneseM. WassermanS.M. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as mono-therapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study Lancet 2012 380 1995 2006 10.1016/S0140-6736(12)61771-1 Search in Google Scholar

[45] Koskinas K.C., Windecker S., Buhayer A., Gencer B., Pedrazzini G., Mueller C., Cook S., Muller O., Matter C.M., Räber L., Heg D., Mach F.: Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clin. Cardiol., 2018; 41: 1513–1520 KoskinasK.C. WindeckerS. BuhayerA. GencerB. PedrazziniG. MuellerC. CookS. MullerO. MatterC.M. RäberL. HegD. MachF. Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial Clin. Cardiol. 2018 41 1513 1520 10.1002/clc.23112649013830421481 Search in Google Scholar

[46] Kruit J.K., Groen A.K., van Berkel T.J., Kuipers F.: Emerging roles of the intestine in control of cholesterol metabolism. World J. Gastroenterol., 2006; 12: 6429–6439 KruitJ.K. GroenA.K. van BerkelT.J. KuipersF. Emerging roles of the intestine in control of cholesterol metabolism World J. Gastroenterol. 2006 12 6429 6439 10.3748/wjg.v12.i40.6429410063117072974 Search in Google Scholar

[47] Kühnast S., Van Der Hoorn J.W., Pieterman E.J., van den Hoek A.M., Sasiela W.J., Gusarova V., Peyman A., Schäfer H.L., Schwahn U., Jukema J.W., Princen H.M.: Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J. Lipid Res., 2014; 55: 2103–2112 KühnastS. Van Der HoornJ.W. PietermanE.J. van den HoekA.M. SasielaW.J. GusarovaV. PeymanA. SchäferH.L. SchwahnU. JukemaJ.W. PrincenH.M. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin J. Lipid Res. 2014 55 2103 2112 10.1194/jlr.M051326417400325139399 Search in Google Scholar

[48] Labonté P., Begley S., Guévin C., Asselin M.C., Nassoury N., Mayer G., Prat A., Seidah N.G.: PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology, 2009; 50: 17–24 LabontéP. BegleyS. GuévinC. AsselinM.C. NassouryN. MayerG. PratA. SeidahN.G. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression Hepatology 2009 50 17 24 10.1002/hep.2291119489072 Search in Google Scholar

[49] Leak T.S., Keene K.L., Langefeld C.D., Gallagher C.J., Mychaleckyj J.C., Freedman B.I., Bowden D.W., Rich S.S., Sale M.M.: Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American population. Mol. Genet. Metab., 2007; 92: 145–150 LeakT.S. KeeneK.L. LangefeldC.D. GallagherC.J. MychaleckyjJ.C. FreedmanB.I. BowdenD.W. RichS.S. SaleM.M. Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American population Mol. Genet. Metab. 2007 92 145 150 10.1016/j.ymgme.2007.05.014275282417618154 Search in Google Scholar

[50] Leiva E., Wehinger S.R., Guzmán L., Orrego R.: Role of oxidized LDL in atherosclerosis. W: Hypercholesterolemia, red.: S.A. Kumar. IntechOpen Limited, London 2015, 55–77 LeivaE. WehingerS.R. GuzmánL. OrregoR. Role of oxidized LDL in atherosclerosis W: Hypercholesterolemia red.: KumarS.A. IntechOpen Limited London 2015 55 77 10.5772/59375 Search in Google Scholar

[51] Leritz E.C., McGlinchey R.E., Salat D.H., Milberg W.P.: Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory. Metab. Brain Dis., 2016; 31: 465–473 LeritzE.C. McGlincheyR.E. SalatD.H. MilbergW.P. Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory Metab. Brain Dis. 2016 31 465 473 10.1007/s11011-016-9797-y491347426873100 Search in Google Scholar

[52] Levels J.H.M., Marquart J.A., Abraham P.R., van den Ende A.E., Molhuizen H.O.F., van Deventer S.J.H., Meijers J.C.M.: Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect. Immun., 2005; 73: 2321–2326 LevelsJ.H.M. MarquartJ.A. AbrahamP.R. van den EndeA.E. MolhuizenH.O.F. van DeventerS.J.H. MeijersJ.C.M. Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein Infect. Immun. 2005 73 2321 2326 10.1128/IAI.73.4.2321-2326.2005 Search in Google Scholar

[53] Li T., Jiang S., Ni B., Cui Q., Liu Q., Zhao H.: Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018. Int. J. Mol. Sci., 2019; 20: 4513 LiT. JiangS. NiB. CuiQ. LiuQ. ZhaoH. Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018 Int. J. Mol. Sci. 2019 20 4513 10.3390/ijms20184513 Search in Google Scholar

[54] Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R.: 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J., 2020; 41: 111–188 MachF. BaigentC. CatapanoA.L. KoskinasK.C. CasulaM. BadimonL. ChapmanM.J. De BackerG.G. DelgadoV. FerenceB.A. GrahamI.M. HallidayA. LandmesserU. MihaylovaB. PedersenT.R. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk Eur. Heart J. 2020 41 111 188 10.1093/eurheartj/ehz455 Search in Google Scholar

[55] Małuch I., Walewska A., Sikorska E., Prahl A.: Konwertazy probiałkowe – rodzina proteaz serynowych o szerokim spektrum funkcji fizjologicznych. Post. Bioch., 2016; 62: 472–481 MałuchI. WalewskaA. SikorskaE. PrahlA. Konwertazy probiałkowe – rodzina proteaz serynowych o szerokim spektrum funkcji fizjologicznych Post. Bioch. 2016 62 472 481 Search in Google Scholar

[56] Mannarino M.R., Sahebkar A., Bianconi V., Serban M.C., Banach M., Pirro M.: PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results? J. Clin. Lipidol., 2018; 12: 1123–1132 MannarinoM.R. SahebkarA. BianconiV. SerbanM.C. BanachM. PirroM. PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results? J. Clin. Lipidol. 2018 12 1123 1132 10.1016/j.jacl.2018.05.012 Search in Google Scholar

[57] Mbikay M., Mayne J., Seidah N.G., Chrétien M.: Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms. Med. Hypotheses, 2007; 69: 1010–1017 MbikayM. MayneJ. SeidahN.G. ChrétienM. Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms Med. Hypotheses 2007 69 1010 1017 10.1016/j.mehy.2007.03.018 Search in Google Scholar

[58] Monami M., Sesti G., Mannucci E.: PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes. Metab., 2019; 21: 903–908 MonamiM. SestiG. MannucciE. PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes Diabetes Obes. Metab. 2019 21 903 908 10.1111/dom.13599 Search in Google Scholar

[59] Muldoon M.F., Barger S.D., Ryan C.M., Flory J.D., Lehoczky J.P., Matthews K.A., Manuck S.B.: Effects of lovastatin on cognitive function and psychological well-being. Am. J. Med., 2000; 108: 538–546 MuldoonM.F. BargerS.D. RyanC.M. FloryJ.D. LehoczkyJ.P. MatthewsK.A. ManuckS.B. Effects of lovastatin on cognitive function and psychological well-being Am. J. Med. 2000 108 538 546 10.1016/S0002-9343(00)00353-3 Search in Google Scholar

[60] Naureckiene S., Ma L., Sreekumar K., Purandare U., Lo C.F., Huang Y., Chiang L.W., Grenier J.M., Ozenberger B.A., Jacobsen J.S., Kennedy J.D., DiStefano P.S., Wood A., Bingham B.: Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys., 2003; 420: 55–67 NaureckieneS. MaL. SreekumarK. PurandareU. LoC.F. HuangY. ChiangL.W. GrenierJ.M. OzenbergerB.A. JacobsenJ.S. KennedyJ.D. DiStefanoP.S. WoodA. BinghamB. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys. 2003 420 55 67 10.1016/j.abb.2003.09.01114622975 Search in Google Scholar

[61] Nishikido T., Ray K.K.: Inclisiran for the treatment of dyslipidemia. Expert Opin. Investig. Drugs, 2018; 27: 287–294 NishikidoT. RayK.K. Inclisiran for the treatment of dyslipidemia Expert Opin. Investig. Drugs 2018 27 287 294 10.1080/13543784.2018.144243529451410 Search in Google Scholar

[62] Norata G.D., Tavori H., Pirillo A., Fazio S., Catapano A.L.: Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering. Cardiovasc. Res., 2016; 112: 429–442 NorataG.D. TavoriH. PirilloA. FazioS. CatapanoA.L. Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering Cardiovasc. Res. 2016 112 429 442 10.1093/cvr/cvw194503195027496869 Search in Google Scholar

[63] Okopień B., Bułdak Ł., Bołdys A.: Current and future trends in the lipid lowering therapy. Pharmacol. Rep., 2016; 68: 737–747 OkopieńB. BułdakŁ. BołdysA. Current and future trends in the lipid lowering therapy Pharmacol. Rep. 2016 68 737 747 10.1016/j.pharep.2016.03.01627180022 Search in Google Scholar

[64] Pasta A., Cremonini A.L., Pisciotta L., Buscaglia A., Porto I., Barra F., Ferrero S., Brunelli C., Rosa G.M.: PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin. Pharmacother., 2020; 21: 353–363 PastaA. CremoniniA.L. PisciottaL. BuscagliaA. PortoI. BarraF. FerreroS. BrunelliC. RosaG.M. PCSK9 inhibitors for treating hypercholesterolemia Expert Opin. Pharmacother. 2020 21 353 363 10.1080/14656566.2019.170297031893957 Search in Google Scholar

[65] Pavlakou P., Liberopoulos E., Dounousi E., Elisaf M.: PCSK9 in chronic kidney disease. Int. Urol. Nephrol., 2017; 49: 1015–1024 PavlakouP. LiberopoulosE. DounousiE. ElisafM. PCSK9 in chronic kidney disease Int. Urol. Nephrol. 2017 49 1015 1024 10.1007/s11255-017-1505-228084558 Search in Google Scholar

[66] Perego C., Da Dalt L., Pirillo A., Galli A., Catapano A.L., Norata G.D.: Cholesterol metabolism, pancreatic β-cell function and diabetes. Biochim. Biophys. Acta Mol. Basis Dis., 2019; 1865: 2149–2156 PeregoC. Da DaltL. PirilloA. GalliA. CatapanoA.L. NorataG.D. Cholesterol metabolism, pancreatic β-cell function and diabetes Biochim. Biophys. Acta Mol. Basis Dis. 2019 1865 2149 2156 10.1016/j.bbadis.2019.04.01231029825 Search in Google Scholar

[67] Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J., Nassoury N., Mayer H., Nimpf J., Prat A., Seidah N.G.: The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem., 2008; 283: 2363–2372 PoirierS. MayerG. BenjannetS. BergeronE. MarcinkiewiczJ. NassouryN. MayerH. NimpfJ. PratA. SeidahN.G. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 J. Biol. Chem. 2008 283 2363 2372 10.1074/jbc.M70809820018039658 Search in Google Scholar

[68] Postmus I., Trompet S., de Craen A.J., Buckley B.M., Ford I., Stott D.J., Sattar N., Slagboom P.E., Westendorp R.G., Jukema J.W.: PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. J. Lipid Res., 2013; 54: 561–566 PostmusI. TrompetS. de CraenA.J. BuckleyB.M. FordI. StottD.J. SattarN. SlagboomP.E. WestendorpR.G. JukemaJ.W. PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population J. Lipid Res. 2013 54 561 566 10.1194/jlr.M033969 Search in Google Scholar

[69] Preiss D., Seshasai S.R., Welsh P., Murphy S.A., Ho J.E., Waters D.D., DeMicco D.A., Barter P., Cannon C.P., Sabatine M.S., Braunwald E., Kastelein J.J., de Lemos J.A., Blazing M.A., Pedersen T.R. i wsp.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA, 2011; 305: 2556–2564 PreissD. SeshasaiS.R. WelshP. MurphyS.A. HoJ.E. WatersD.D. DeMiccoD.A. BarterP. CannonC.P. SabatineM.S. BraunwaldE. KasteleinJ.J. de LemosJ.A. BlazingM.A. PedersenT.R. i wsp. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis JAMA 2011 305 2556 2564 10.1001/jama.2011.86021693744 Search in Google Scholar

[70] Ramanathan A., Gusarova V., Stahl N., Gurnett-Bander A., Kyratsous C.A.: Alirocumab, a therapeutic human antibody to PCSK9, does not affect CD81 levels or hepatitis C virus entry and replication into hepatocytes. PLoS One, 2016; 11: e0154498 RamanathanA. GusarovaV. StahlN. Gurnett-BanderA. KyratsousC.A. Alirocumab, a therapeutic human antibody to PCSK9, does not affect CD81 levels or hepatitis C virus entry and replication into hepatocytes PLoS One 2016 11 e0154498 10.1371/journal.pone.0154498484599827115873 Search in Google Scholar

[71] Ramin-Mangata S., Blanchard V., Lambert G.: Key aspects of PCSK9 inhibition beyond LDL lowering. Curr. Opin. Lipidol., 2018; 29: 453–458 Ramin-MangataS. BlanchardV. LambertG. Key aspects of PCSK9 inhibition beyond LDL lowering Curr. Opin. Lipidol. 2018 29 453 458 10.1097/MOL.000000000000055130199407 Search in Google Scholar

[72] Ramos-Molina B., Martin M.G., Lindberg I.: PCSK1 variants and human obesity. Prog. Mol. Biol. Transl. Sci., 2016; 140: 47–74 Ramos-MolinaB. MartinM.G. LindbergI. PCSK1 variants and human obesity Prog. Mol. Biol. Transl. Sci. 2016 140 47 74 10.1016/bs.pmbts.2015.12.001608239027288825 Search in Google Scholar

[73] Ray K.K., Corral P., Morales E., Nicholls S.J.: Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: Current and future options. Lancet, 2019; 394: 697–708 RayK.K. CorralP. MoralesE. NichollsS.J. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: Current and future options Lancet 2019 394 697 708 10.1016/S0140-6736(19)31950-6 Search in Google Scholar

[74] Ricci C., Ruscica M., Camera M., Rossetti L., Macchi C., Colciago A., Zanotti I., Lupo M.G., Adorni M.P., Cicero A.F., Fogacci F., Corsini A., Ferri N.: PCSK9 induces a pro-inflammatory response in macrophages. Sci. Rep., 2018; 8: 2267 RicciC. RuscicaM. CameraM. RossettiL. MacchiC. ColciagoA. ZanottiI. LupoM.G. AdorniM.P. CiceroA.F. FogacciF. CorsiniA. FerriN. PCSK9 induces a pro-inflammatory response in macrophages Sci. Rep. 2018 8 2267 10.1038/s41598-018-20425-x Search in Google Scholar

[75] Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M. Jr, Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J., JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Eng. J. Med., 2008; 359: 2195–2207 RidkerP.M. DanielsonE. FonsecaF.A. GenestJ. GottoA.M.Jr KasteleinJ.J. KoenigW. LibbyP. LorenzattiA.J. MacFadyenJ.G. NordestgaardB.G. ShepherdJ. WillersonJ.T. GlynnR.J. JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N. Eng. J. Med. 2008 359 2195 2207 10.1056/NEJMoa0807646 Search in Google Scholar

[76] Ridker P.M., Tardif J.C., Amarenco P., Duggan W., Glynn R.J., Jukema J.W., Kastelein J.J., Kim A.M., Koenig W., Nissen S., Revkin J., Rose L.M., Santos R.D., Schwartz P.F. i wsp.: Lipid-reduction variability and antidrug-antibody formation with bococizumab. N. Eng. J. Med., 2017; 376: 1517–1526 RidkerP.M. TardifJ.C. AmarencoP. DugganW. GlynnR.J. JukemaJ.W. KasteleinJ.J. KimA.M. KoenigW. NissenS. RevkinJ. RoseL.M. SantosR.D. SchwartzP.F. i wsp. Lipid-reduction variability and antidrug-antibody formation with bococizumab N. Eng. J. Med. 2017 376 1517 1526 10.1056/NEJMoa1614062 Search in Google Scholar

[77] Roth E.M., Goldberg A.C., Catapano A.L., Torri A., Yancopoulos G.D., Stahl N., Brunet A., Lecorps G., Colhoun H.M.: Antidrug antibodies in patients treated with alirocumab. N. Eng. J. Med., 2017; 376: 1589–1590 RothE.M. GoldbergA.C. CatapanoA.L. TorriA. YancopoulosG.D. StahlN. BrunetA. LecorpsG. ColhounH.M. Antidrug antibodies in patients treated with alirocumab N. Eng. J. Med. 2017 376 1589 1590 10.1056/NEJMc1616623 Search in Google Scholar

[78] Rouillé Y., Martin S., Steiner D.F.: Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J. Biol. Chem., 1995; 270: 26488–26496 RouilléY. MartinS. SteinerD.F. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide J. Biol. Chem. 1995 270 26488 26496 10.1074/jbc.270.44.26488 Search in Google Scholar

[79] Ruscica M., Ricci C., Macchi C., Magni P., Cristofani R., Liu J., Corsini A., Ferri N.: Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J. Biol. Chem, 2016; 291: 3508–3519 RuscicaM. RicciC. MacchiC. MagniP. CristofaniR. LiuJ. CorsiniA. FerriN. Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line J. Biol. Chem 2016 291 3508 3519 10.1074/jbc.M115.664706 Search in Google Scholar

[80] Sabatine M.S.: PCSK9 inhibitors: Clinical evidence and implementation. Nat. Rev. Cardiol., 2019; 16: 155–165 SabatineM.S. PCSK9 inhibitors: Clinical evidence and implementation Nat. Rev. Cardiol. 2019 16 155 165 10.1038/s41569-018-0107-8 Search in Google Scholar

[81] Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., Kuder J.F., Wang H., Liu T., Wasserman S.M., Sever P.S., Pedersen T.R., FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Eng. J. Med., 2017; 376: 1713–1722 SabatineM.S. GiuglianoR.P. KeechA.C. HonarpourN. WiviottS.D. MurphyS.A. KuderJ.F. WangH. LiuT. WassermanS.M. SeverP.S. PedersenT.R. FOURIER Steering Committee and Investigators Evolocumab and clinical outcomes in patients with cardiovascular disease N. Eng. J. Med. 2017 376 1713 1722 10.1056/NEJMoa1615664 Search in Google Scholar

[82] Sattar N., Preiss D., Murray H.M., Welsh P., Buckley B.M., de Craen A.J., Seshasai S.R., McMurray J.J., Freeman D.J., Jukema J.W., Macfarlane P.W., Packard C.J., Stott D.J., Westendorp R.G., Shepherd J.: Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375: 735–742 SattarN. PreissD. MurrayH.M. WelshP. BuckleyB.M. de CraenA.J. SeshasaiS.R. McMurrayJ.J. FreemanD.J. JukemaJ.W. MacfarlaneP.W. PackardC.J. StottD.J. WestendorpR.G. ShepherdJ. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials Lancet 2010 375 735 742 10.1016/S0140-6736(09)61965-6 Search in Google Scholar

[83] Scamuffa N., Calvo F., Chrétien M., Seidah N.G., Khatib A.M.: Proprotein convertases: Lessons from knockouts. FASEB J., 2006; 20: 1954–1963 ScamuffaN. CalvoF. ChrétienM. SeidahN.G. KhatibA.M. Proprotein convertases: Lessons from knockouts FASEB J. 2006 20 1954 1963 10.1096/fj.05-5491rev Search in Google Scholar

[84] Schmidt A.F., Swerdlow D.I., Holmes M.V., Patel R.S., Fairhurst-Hunter Z., Lyall D.M., Hartwig F.P., Horta B.L., Hyppönen E., Power C., Moldovan M., van Iperen E., Hovingh G.K., Demuth I., Norman K.: PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation study. Lancet Diabetes Endocrinol., 2017; 5: 97–105 SchmidtA.F. SwerdlowD.I. HolmesM.V. PatelR.S. Fairhurst-HunterZ. LyallD.M. HartwigF.P. HortaB.L. HyppönenE. PowerC. MoldovanM. van IperenE. HovinghG.K. DemuthI. NormanK. PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation study Lancet Diabetes Endocrinol. 2017 5 97 105 10.1016/S2213-8587(16)30396-5 Search in Google Scholar

[85] Schmidt R.J., Beyer T.P., Bensch W.R., Qian Y.W., Lin A., Kowala M., Alborn W.E., Konrad R.J., Cao G.: Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem. Biophys. Res. Commun., 2008; 370: 634–640 SchmidtR.J. BeyerT.P. BenschW.R. QianY.W. LinA. KowalaM. AlbornW.E. KonradR.J. CaoG. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo Biochem. Biophys. Res. Commun. 2008 370 634 640 10.1016/j.bbrc.2008.04.00418406350 Search in Google Scholar

[86] Schwartz G.G., Steg P.G., Szarek M., Bhatt D.L., Bittner V.A., Diaz R., Edelberg J.M., Goodman S.G., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Mahaffey K.W., Moryusef A., Pordy R., Quintero K., Roe M.T.: Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Eng. J. Med., 2018; 379: 2097–2107 SchwartzG.G. StegP.G. SzarekM. BhattD.L. BittnerV.A. DiazR. EdelbergJ.M. GoodmanS.G. HanotinC. HarringtonR.A. JukemaJ.W. LecorpsG. MahaffeyK.W. MoryusefA. PordyR. QuinteroK. RoeM.T. Alirocumab and cardiovascular outcomes after acute coronary syndrome N. Eng. J. Med. 2018 379 2097 2107 10.1056/NEJMoa180117430403574 Search in Google Scholar

[87] Seidah N.G.: PCSK9 as a therapeutic target of dyslipidemia. Expert Opin. Ther. Targets, 2009; 13: 19–28 SeidahN.G. PCSK9 as a therapeutic target of dyslipidemia Expert Opin. Ther. Targets 2009 13 19 28 10.1517/1472822080260071519063703 Search in Google Scholar

[88] Seidah N.G.: The proprotein convertases, 20 years later. Methods Mol. Biol., 2011; 768: 23–57 SeidahN.G. The proprotein convertases, 20 years later Methods Mol. Biol. 2011 768 23 57 10.1007/978-1-61779-204-5_321805237 Search in Google Scholar

[89] Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., Basak A., Prat A., Chretien M.: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A., 2003; 100: 928–933 SeidahN.G. BenjannetS. WickhamL. MarcinkiewiczJ. JasminS.B. StifaniS. BasakA. PratA. ChretienM. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation Proc. Natl. Acad. Sci. U. S. A. 2003 100 928 933 10.1073/pnas.033550710029870312552133 Search in Google Scholar

[90] Seidah N.G., Hamelin J., Mamarbachi M., Dong W., Tardos H., Mbikay M., Chretien M., Day R.: cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc. Natl. Acad. Sci. U. S. A., 1996; 93: 3388–3393 SeidahN.G. HamelinJ. MamarbachiM. DongW. TardosH. MbikayM. ChretienM. DayR. cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases Proc. Natl. Acad. Sci. U. S. A. 1996 93 3388 3393 10.1073/pnas.93.8.3388396188622945 Search in Google Scholar

[91] Seidah N.G., Prat A.: The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov., 2012; 11: 367–383 SeidahN.G. PratA. The biology and therapeutic targeting of the proprotein convertases Nat. Rev. Drug Discov. 2012 11 367 383 10.1038/nrd369922679642 Search in Google Scholar

[92] Sharotri V., Collier D.M., Olson D.R., Zhou R., Snyder P.M.: Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J. Biol. Chem., 2012; 287: 19266–19274 SharotriV. CollierD.M. OlsonD.R. ZhouR. SnyderP.M. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9) J. Biol. Chem. 2012 287 19266 19274 10.1074/jbc.M112.363382336595822493497 Search in Google Scholar

[93] Shrestha P., van de Sluis B., Dullaart R.P.F., van den Born J.: Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cell. Signal., 2019; 55: 53–64 ShresthaP. van de SluisB. DullaartR.P.F. van den BornJ. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia Cell. Signal. 2019 55 53 64 10.1016/j.cellsig.2018.12.001 Search in Google Scholar

[94] Steffens D., Bramlage P., Scheeff C., Kasner M., Hassanein A., Friebel J., Rauch-Kröhnert U.: PCSK9 inhibitors and cardiovascular outcomes. Expert Opin. Biol. Ther., 2020; 20: 35–47 SteffensD. BramlageP. ScheeffC. KasnerM. HassaneinA. FriebelJ. Rauch-KröhnertU. PCSK9 inhibitors and cardiovascular outcomes Expert Opin. Biol. Ther. 2020 20 35 47 10.1080/14712598.2020.1677604 Search in Google Scholar

[95] Stoekenbroek R.M., Lambert G., Cariou B., Hovingh G.K.: Inhibiting PCSK9 – biology beyond LDL control. Nat. Rev. Endocrinol., 2018; 15: 52–62 StoekenbroekR.M. LambertG. CariouB. HovinghG.K. Inhibiting PCSK9 – biology beyond LDL control Nat. Rev. Endocrinol. 2018 15 52 62 10.1038/s41574-018-0110-5 Search in Google Scholar

[96] Suchy D., Łabuzek K., Stadnicki A., Okopień B.: Ezetimibe – a new approach in hypercholesterolemia management. Pharmacol. Rep., 2011; 63: 1335–1348 SuchyD. ŁabuzekK. StadnickiA. OkopieńB. Ezetimibe – a new approach in hypercholesterolemia management Pharmacol. Rep. 2011 63 1335 1348 10.1016/S1734-1140(11)70698-3 Search in Google Scholar

[97] Syed G.H., Tang H., Khan M., Hassanein T., Liu J., Siddiqui A.: Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J. Virol., 2014; 88: 2519–2529 SyedG.H. TangH. KhanM. HassaneinT. LiuJ. SiddiquiA. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation J. Virol. 2014 88 2519 2529 10.1128/JVI.02727-13 Search in Google Scholar

[98] Tadros H., Chrétien M., Mbikay M.: The testicular germ-cell pro-tease PC4 is also expressed in macrophage-like cells of the ovary. J. Reprod. Immunol., 2001; 49: 133–152 TadrosH. ChrétienM. MbikayM. The testicular germ-cell pro-tease PC4 is also expressed in macrophage-like cells of the ovary J. Reprod. Immunol. 2001 49 133 152 10.1016/S0165-0378(00)00085-1 Search in Google Scholar

[99] Tang Z.H., Peng J., Ren Z., Yang J., Li T.T., Li T.H., Wang Z., Wei D.H., Liu L.S., Zheng X.L., Jiang Z.S.: New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis, 2017; 262: 113–122 TangZ.H. PengJ. RenZ. YangJ. LiT.T. LiT.H. WangZ. WeiD.H. LiuL.S. ZhengX.L. JiangZ.S. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway Atherosclerosis 2017 262 113 122 10.1016/j.atherosclerosis.2017.04.02328535426 Search in Google Scholar

[100] Taskinen M.R., Björnson E., Andersson L., Kahri J., Porthan K., Matikainen N., Söderlund S., Pietiläinen K., Hakkarainen A., Lund-bom N., Nilsson R., Ståhlman M., Adiels M., Parini P., Packard C.: Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipo-proteins in type II diabetic subjects. J. Clin. Lipidol., 2020; 14: 77–87 TaskinenM.R. BjörnsonE. AnderssonL. KahriJ. PorthanK. MatikainenN. SöderlundS. PietiläinenK. HakkarainenA. Lund-bomN. NilssonR. StåhlmanM. AdielsM. PariniP. PackardC. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipo-proteins in type II diabetic subjects J. Clin. Lipidol. 2020 14 77 87 10.1016/j.jacl.2019.12.00331917184 Search in Google Scholar

[101] Tavori H., Giunzioni I., Predazzi I.M., Plubell D., Shivinsky A., Miles J., Devay R.M., Liang H., Rashid S., Linton M.F., Fazio S.: Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc. Res., 2016, 110: 268–278 TavoriH. GiunzioniI. PredazziI.M. PlubellD. ShivinskyA. MilesJ. DevayR.M. LiangH. RashidS. LintonM.F. FazioS. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms Cardiovasc. Res. 2016 110 268 278 10.1093/cvr/cvw053483663126980204 Search in Google Scholar

[102] Thomas G.: Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol., 2002; 3: 753–766 ThomasG. Furin at the cutting edge: From protein traffic to embryogenesis and disease Nat. Rev. Mol. Cell Biol. 2002 3 753 766 10.1038/nrm934196475412360192 Search in Google Scholar

[103] Van Bruggen F.H., Nijhuis G.B.J., Zuidema S.U., Luijendijk H.: Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: A systematic review. Expert Rev. Clin. Pharmacol., 2020; 13: 787–796 Van BruggenF.H. NijhuisG.B.J. ZuidemaS.U. LuijendijkH. Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: A systematic review Expert Rev. Clin. Pharmacol. 2020 13 787 796 10.1080/17512433.2020.178783232597252 Search in Google Scholar

[104] Walley K.R., Thain K.R., Russell J.A., Reilly M.P., Meyer N.J., Ferguson J.F., Christie J.D., Nakada T.A., Fjell C.D., Thair S.A., Cirstea M.S., Boyd J.H.: PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci. Transl. Med., 2014; 6: 258ra143 WalleyK.R. ThainK.R. RussellJ.A. ReillyM.P. MeyerN.J. FergusonJ.F. ChristieJ.D. NakadaT.A. FjellC.D. ThairS.A. CirsteaM.S. BoydJ.H. PCSK9 is a critical regulator of the innate immune response and septic shock outcome Sci. Transl. Med. 2014 6 258ra143 10.1126/scitranslmed.3008782434214725320235 Search in Google Scholar

[105] Williams D.M., Finan C., Schmidt A.F., Burgess S., Hingorani A.D.: Lipid lowering and Alzheimer disease risk: A Mendelian randomization study. Ann. Neurol., 2020, 87: 30–39 WilliamsD.M. FinanC. SchmidtA.F. BurgessS. HingoraniA.D. Lipid lowering and Alzheimer disease risk: A Mendelian randomization study Ann. Neurol. 2020 87 30 39 10.1002/ana.25642694451031714636 Search in Google Scholar

[106] Wu C.Y., Tang Z.H., Jiang L., Li X.F., Jiang Z.S., Liu L.S.: PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol. Cell. Biochem., 2012, 359: 347–358 WuC.Y. TangZ.H. JiangL. LiX.F. JiangZ.S. LiuL.S. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway Mol. Cell. Biochem. 2012 359 347 358 10.1007/s11010-011-1028-621847580 Search in Google Scholar

[107] Yano H., Horinaka S., Ishimitsu T.: Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J. Cardiol., 2020; 75: 289–295 YanoH. HorinakaS. IshimitsuT. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome J. Cardiol. 2020 75 289 295 10.1016/j.jjcc.2019.08.00231495548 Search in Google Scholar

[108] Yurtseven E., Ural D., Baysal K., Tokgözoğlu L.: An update on the role of PCSK9 in atherosclerosis. J. Atheroscler. Thromb., 2020; 27: 909–918 YurtsevenE. UralD. BaysalK. TokgözoğluL. An update on the role of PCSK9 in atherosclerosis J. Atheroscler. Thromb. 2020 27 909 918 10.5551/jat.55400750872132713931 Search in Google Scholar

[109] Zheng-Lin B., Ortiz A.: Lipid management in chronic kidney disease: Systematic review of PCSK9 targeting. Drugs, 2018; 78: 215–229 Zheng-LinB. OrtizA. Lipid management in chronic kidney disease: Systematic review of PCSK9 targeting Drugs 2018 78 215 229 10.1007/s40265-017-0858-229299849 Search in Google Scholar

[110] Zimetti F., Caffarra P., Ronda N., Favari E., Adorni M.P., Zanotti I., Bernini F., Barocco F., Spallazzi M., Galimberti D., Ricci C., Ruscica M., Corsini A., Ferri N.: Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease. J. Alzheimers Dis., 2017; 55: 315–320 ZimettiF. CaffarraP. RondaN. FavariE. AdorniM.P. ZanottiI. BerniniF. BaroccoF. SpallazziM. GalimbertiD. RicciC. RuscicaM. CorsiniA. FerriN. Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease J. Alzheimers Dis. 2017 55 315 320 10.3233/JAD-16041127662294 Search in Google Scholar